Search

Browse by Tags

TypeOneNation

Blogs from JDRF and/or TypeOneNation
Tagged Content List
  • Blog Post: Key Component of Artificial Pancreas Shown Successful in Reducing Hypoglycemia in People with T1D

    In a study published this month in Diabetes Technology & Therapeutics , researchers concluded that the automatic suspension of insulin delivery by a low glucose suspend (LGS) system greatly reduces the severity and duration of hypoglycemia (extreme low blood sugar) in people with type 1 diabetes...
  • Blog Post: Progress on the Artificial Pancreas

    I’m pleased to share the news that on Thursday , December 1, the U.S. Food and Drug Administration (FDA) issued artificial pancreas (AP) draft guidance. While the draft guidance is still under review, our initial analysis suggests that it affirmatively addresses many of JDRF’s key issues...
  • Blog Post: The Artificial Pancreas – Taking the Guesswork out of Diabetes

    Imagine having to do math before and after every meal you eat, because your life depends on it. That is the reality for millions of people living with type 1 diabetes. Before digging in to a savory plate of food before them, people with type 1 diabetes must calculate the number of carbohydrates about...
Page 1 of 1 (3 items)

ABOUT TYPEONENATION
TypeOneNation is a vibrant social network created especially for and by people with type 1 diabetes and their loved ones. More about TypeOneNation

Terms of Service | Privacy Policy

 
DONATION
Please consider making a donation to JDRF to support research toward better treatments and a cure for type 1 diabetes.

SUPPORT
For help on TypeOneNation you can view answers to common support questions or contact us.


JDRF is the worldwide leader for research to prevent, better treat, and ultimately cure type 1 diabetes. It sets the global agenda for diabetes research, and is the largest charitable funder and advocate of diabetes science worldwide. More about JDRF TypeOneNation is funded through an educational grant from Novo Nordisk through its Changing Diabetes© leadership initiative. More about Novo Nordisk